Conca, V., Moretto, R., Lonardi, S., Antoniotti, C., Pietrantonio, F., Marmorino, F., Antonuzzo, L., Borelli, B., Perissinotto, E., Randon, G., Germani, M. M., Toma, I., Sullo, F., Masi, G., Pozzo, C., Morelli, C., Buonadonna, A., Boni, L., Rossini, D., Cremolini, C. (2025). Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable
            <i>RAS</i>
            and
            <i>BRAF</i>
            wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3512